Key result
Cardiac resynchronization therapy was associated with 15% and 53% mortality at 1 and 5 years, with ischemic heart disease, lower LVEF, and higher NYHA class predicting mortality.
Why the study?
What are the predictors of mortality and long-term clinical effects of cardiac resynchronization therapy in patients with heart failure?
Cohort (n=179)
What are the predictors of mortality and long-term clinical effects of cardiac resynchronization therapy in patients with heart failure?
In patients receiving CRT, clinical benefits are sustained at 5 years, with non-ischemic patients showing further LVEF improvements, while ischemic etiology, low baseline LVEF, and lack of early symptomatic response predict long-term mortality.
No takes yet. Share an insight, caveat, or question.
May inform CRT risk stratification in HF; leaves open need for randomized confirmation of long-term LVEF gains.
Kronborg et al. (2008) conducted a cohort in Heart failure (n=179). Cardiac resynchronization therapy was evaluated on Mortality. Cardiac resynchronization therapy was associated with 15% and 53% mortality at 1 and 5 years, with ischemic heart disease, lower LVEF, and higher NYHA class predicting mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: